Johnson & Johnson surpassed Q4 earnings expectations and provided optimistic guidance for 2012, highlighting strong growth in pharmaceuticals and strategic acquisitions. Despite some margin pressures and ongoing remediation efforts, management's confident tone and robust pipeline support a positive short-term outlook for the stock.

[1]